Clearmind Announces Positive Results for Intranasal MEAI - BioTuesdays

Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, ...

Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated…

Clearmind announces positive results for intranasal MEAI - BioTuesdays

Clearmind Medical (NASDAQ: CMND; FSE: CWY0) has announced positive permeation study results from its ongoing intranasal MEAI development program. According to Clearmind, early-stage studies of its intranasal MEAI formulation have generated highly promising results, supporting the continued development of this innovative treatment approach as a differentiated therapeutic candidate for mental-health disorders, including alcohol use disorder (AUD),…